Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2016 - 2019)

Historic Non-Current Deffered Revenue for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Q3 2019 value amounting to $900000.0.

  • Enanta Pharmaceuticals' Non-Current Deffered Revenue rose 5177.07% to $900000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $900000.0, marking a year-over-year increase of 5177.07%. This contributed to the annual value of $900000.0 for FY2019, which is 5177.07% up from last year.
  • As of Q3 2019, Enanta Pharmaceuticals' Non-Current Deffered Revenue stood at $900000.0, which was up 5177.07% from $923000.0 recorded in Q2 2019.
  • In the past 5 years, Enanta Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $923000.0 in Q2 2019 and a low of $161000.0 during Q1 2015
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $674000.0 (2018), whereas its average is $650789.5.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 32222.22% in 2015, then crashed by 1406.47% in 2018.
  • Over the past 5 years, Enanta Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $646000.0 in 2015, then rose by 8.51% to $701000.0 in 2016, then fell by 6.7% to $654000.0 in 2017, then increased by 3.06% to $674000.0 in 2018, then skyrocketed by 33.53% to $900000.0 in 2019.
  • Its Non-Current Deffered Revenue was $900000.0 in Q3 2019, compared to $923000.0 in Q2 2019 and $842000.0 in Q1 2019.